Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.47 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.39 |
| ▸ | IGF1R | P08069 | 2/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
| ▸ | INSR | P06213 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10205525 | 0.93 | EGFR (0.47) | EGFRTNK2METALKIGF1R | |
| SCHEMBL10207023 | 0.92 | NTRK1 (0.40) | EGFRTNK2IGF1RCDK1NTRK1 | |
| SCHEMBL10205156 | 0.92 | EGFR (0.47) | EGFRTNK2METALKIGF1R | |
| SCHEMBL10205524 | 0.91 | EGFR (0.58) | EGFRMETALKIGF1RFLT4 | |
| SCHEMBL10205508 | 0.91 | FLT4 (0.45) | EGFRTNK2ALKIGF1RFLT4 | |
| SCHEMBL10206116 | 0.89 | EGFR (0.48) | EGFRALKFLT4PTK2 | |
| SCHEMBL10207050 | 0.88 | TNK2 (0.54) | EGFRTNK2FLT4PTK2CDK1 | |
| SCHEMBL10205217 | 0.88 | TNK2 (0.45) | EGFRTNK2ALKIGF1RFLT4 | |
| SCHEMBL10205921 | 0.87 | TNK2 (0.40) | EGFRTNK2ALKIGF1RFLT4 | |
| SCHEMBL10205526 | 0.86 | WEE1 (0.46) | EGFRTNK2ALKIGF1RPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655358-B1 | OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-11-19 | — | — | EP | disclosed |
| US-8546443-B2 | Benzylic oxindole pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-20120329771-A1 | BENZYLIC OXINDOLE PYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| WO-2012085126-A1 | OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329771-A1 | BENZYLIC OXINDOLE PYRIMIDINES | MKI67, CCNI, CCNB1 | EGFR 1397/4885TNK2 646/4885MET 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.